{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:00:07Z","timestamp":1783033207509,"version":"3.54.6"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00259-025-07264-5","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T23:51:23Z","timestamp":1744329083000},"page":"4200-4212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative diagnostic performance of [68 Ga]Ga-FAPI PET\/CT and [18 F]FDGPET\/CT in biliary tract cancers: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"52","author":[{"given":"Ahmed","family":"Msherghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram","family":"Abuajamieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moad","family":"Ekreer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhab","family":"Alzlitni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hajalamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebtesam","family":"Aldieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dua Rajab","family":"Khalleefah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdussalam I. A.","family":"Alzein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Chenfouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hudi","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmhoimen","family":"Elkhadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Benghatnsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza Adel","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Alsharedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6406-4212","authenticated-orcid":false,"given":"Muhammed","family":"Elhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wintermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"7264_CR1","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.2147\/CMAR.S157092","volume":"11","author":"NU Tariq","year":"2019","unstructured":"Tariq NU, McNamara MG, Valle JW. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res. 2019;11:2623\u201342.","journal-title":"Cancer Manag Res"},{"key":"7264_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.critrevonc.2016.11.012","volume":"116","author":"M Squadroni","year":"2017","unstructured":"Squadroni M, et al. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2017;116:11\u201331.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7264_CR3","doi-asserted-by":"publisher","unstructured":"S\u00f8reide K, et al. Biliary tract cancer. Eur J Surg Oncol. 2024:108489. https:\/\/doi.org\/10.1016\/j.ejso.2024.108489.","DOI":"10.1016\/j.ejso.2024.108489"},{"issue":"10272","key":"7264_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, et al. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"8","key":"7264_CR5","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"1","key":"7264_CR6","doi-asserted-by":"publisher","first-page":"10206","DOI":"10.1038\/s41598-022-13605-3","volume":"12","author":"MJ Kang","year":"2022","unstructured":"Kang MJ, et al. Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. Sci Rep. 2022;12(1):10206.","journal-title":"Sci Rep"},{"issue":"1","key":"7264_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13014-024-02481-y","volume":"19","author":"U Amit","year":"2024","unstructured":"Amit U, et al. Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy. Radiat Oncol. 2024;19(1):102.","journal-title":"Radiat Oncol"},{"issue":"6","key":"7264_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.5858\/arpa.2019-0218-OA","volume":"144","author":"SY Jun","year":"2020","unstructured":"Jun SY, et al. Clinicopathologic and prognostic significance of gallbladder and cystic duct invasion in distal bile duct carcinoma. Arch Pathol Lab Med. 2020;144(6):755\u201363.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"7264_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13244-013-0268-2","volume":"4","author":"R Albazaz","year":"2013","unstructured":"Albazaz R, et al. Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours. Insights Imaging. 2013;4(5):691\u2013700.","journal-title":"Insights Imaging"},{"issue":"1","key":"7264_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/RLU.0000000000000998","volume":"41","author":"L Jiang","year":"2016","unstructured":"Jiang L, et al. Role of 18F-FDG PET\/CT imaging in intrahepatic cholangiocarcinoma. Clin Nucl Med. 2016;41(1):1\u20137.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"7264_CR11","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1572-0241.2007.01710.x","volume":"103","author":"JY Kim","year":"2008","unstructured":"Kim JY, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103(5):1145\u201351.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"7264_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13139-016-0440-y","volume":"51","author":"Y Lee","year":"2017","unstructured":"Lee Y, et al. The role of F-18 FDG PET\/CT in intrahepatic cholangiocarcinoma. Nucl Med Mol Imaging. 2017;51(1):69\u201378.","journal-title":"Nucl Med Mol Imaging"},{"issue":"7","key":"7264_CR13","first-page":"1158","volume":"46","author":"MJ Reinhardt","year":"2005","unstructured":"Reinhardt MJ, et al. Detection of Klatskin\u2019s tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET\/CT: preliminary results for 22 patient studies. J Nucl Med. 2005;46(7):1158\u201363.","journal-title":"J Nucl Med"},{"issue":"4","key":"7264_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jama.2017.19163","volume":"319","author":"MDF McInnes","year":"2018","unstructured":"McInnes MDF, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388\u201396.","journal-title":"JAMA"},{"key":"7264_CR15","unstructured":"Covidence systematic review software, V.H.I., Melbourne, Australia. Available at https:\/\/www.covidence.org. Accessed 20 Mar 2024."},{"issue":"11","key":"7264_CR16","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.7326\/M21-2234","volume":"174","author":"B Yang","year":"2021","unstructured":"Yang B, et al. QUADAS-C: a tool for assessing risk of bias in comparative diagnostic accuracy studies. Ann Intern Med. 2021;174(11):1592\u20139.","journal-title":"Ann Intern Med"},{"issue":"8","key":"7264_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529\u201336.","journal-title":"Ann Intern Med"},{"issue":"1","key":"7264_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55\u201361.","journal-title":"Res Synth Methods"},{"issue":"5","key":"7264_CR19","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s11307-022-01732-2","volume":"24","author":"D Siripongsatian","year":"2022","unstructured":"Siripongsatian D, et al. Comparisons of quantitative parameters of Ga-68-labelled fibroblast activating protein inhibitor (FAPI) PET\/CT and [(18)F]F-FDG PET\/CT in patients with liver malignancies. Mol Imaging Biol. 2022;24(5):818\u201329.","journal-title":"Mol Imaging Biol"},{"issue":"7","key":"7264_CR20","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1007\/s00259-023-06137-z","volume":"50","author":"L Jinghua","year":"2023","unstructured":"Jinghua L, et al. Clinical prospective study of Gallium 68 ((68)Ga)-labeled fibroblast-activation protein inhibitor PET\/CT in the diagnosis of biliary tract carcinoma. Eur J Nucl Med Mol Imaging. 2023;50(7):2152\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"7264_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.122.265215","volume":"64","author":"KM Pabst","year":"2023","unstructured":"Pabst KM, et al. Superior tumor detection for (68)Ga-FAPI-46 versus (18)F-FDG PET\/CT and conventional CT in patients with cholangiocarcinoma. J Nucl Med. 2023;64(7):1049\u201355.","journal-title":"J Nucl Med"},{"issue":"1","key":"7264_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00259-020-04882-z","volume":"48","author":"X Shi","year":"2021","unstructured":"Shi X, et al. Fibroblast imaging of hepatic carcinoma with (68)Ga-FAPI-04 PET\/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging. 2021;48(1):196\u2013203.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7264_CR23","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1097\/RLU.0000000000004641","volume":"48","author":"V Rajaraman","year":"2023","unstructured":"Rajaraman V, et al. Role of 68Ga-FAPI PET\/CT in assessing hepatobiliary malignancies: a prospective pilot study. Clin Nucl Med. 2023;48(6):e281\u20138.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"7264_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/RLU.0000000000005112","volume":"49","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, et al. 68 Ga-FAPI-04 PET\/CT for the evaluation of cholangiocarcinoma: comparison with 18 F-FDG PET\/CT and abdominal 68 Ga-FAPI-04 PET\/MR. Clin Nucl Med. 2024;49(5):409\u201318.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"7264_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1148\/radiol.213118","volume":"304","author":"L Lan","year":"2022","unstructured":"Lan L, et al. Prospective comparison of (68)Ga-FAPI versus (18)F-FDG PET\/CT for tumor staging in biliary tract cancers. Radiology. 2022;304(3):648\u201357.","journal-title":"Radiology"},{"issue":"6","key":"7264_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, et al. (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801\u20135.","journal-title":"J Nucl Med"},{"key":"7264_CR27","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.ctrv.2019.101936","volume":"84","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"7264_CR28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/RLU.0000000000004602","volume":"48","author":"RC Delgado Bolton","year":"2023","unstructured":"Delgado Bolton RC, et al. Are we approaching a change in paradigm in PET\/CT imaging of solid gastrointestinal (or digestive) tract tumors with the clinical application of FAPI imaging? Clin Nucl Med. 2023;48(4):318\u20139.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"7264_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.120.245084","volume":"62","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, et al. FAPI-74 PET\/CT Using Either (18)F-AlF or cold-kit (68)Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62(2):201\u20137.","journal-title":"J Nucl Med"},{"key":"7264_CR30","doi-asserted-by":"publisher","unstructured":"Dong Y, Zhou H, Alhaskawi A, Wang Z, Lai J, Yao C, Liu Z, Hasan Abdullah Ezzi S, Goutham Kota V, Hasan Abdulla Hasan Abdulla M, Lu H. The superiority of fibroblast activation protein inhibitor (FAPI) PET\/CT versus FDG PET\/CT in the diagnosis of various malignancies. Cancers (Basel). 2023;15(4):1193. https:\/\/doi.org\/10.3390\/cancers15041193","DOI":"10.3390\/cancers15041193"},{"issue":"4","key":"7264_CR31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2214\/AJR.22.28402","volume":"220","author":"Z Gege","year":"2023","unstructured":"Gege Z, Xueju W, Bin J. Head-To-head comparison of (68)Ga-FAPI PET\/CT and FDG PET\/CT for the detection of peritoneal metastases: systematic review and meta-analysis. AJR Am J Roentgenol. 2023;220(4):490\u20138.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"7264_CR32","first-page":"35","volume":"27","author":"C Gao","year":"2024","unstructured":"Gao C, et al. Head to head comparison of (68)Ga-FAPI PET\/CT with (18)F-FDG PET\/CT in primary and metastatic lesions of gastric tumor: a systematic review and meta-analysis. Hell J Nucl Med. 2024;27(1):35\u201345.","journal-title":"Hell J Nucl Med"},{"issue":"3","key":"7264_CR33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2967\/jnumed.123.266652","volume":"65","author":"N Hirmas","year":"2024","unstructured":"Hirmas N, et al. Diagnostic accuracy 68Ga-FAPI versus 18F-FDG PET in patients with various malignancies. J Nucl Med. 2024;65(3):372\u20138.","journal-title":"J Nucl Med"},{"key":"7264_CR34","doi-asserted-by":"publisher","unstructured":"Xi Y, Sun Y, Gu B, Bian L, Song S.\u00a0Evaluation of 68Ga-FAPI PET\/CT and 18F-FDG PET\/CT for the diagnosis of recurrent colorectal cancers. Clin Transl Radiat Oncol. 2024;49:100848.\u00a0https:\/\/doi.org\/10.1016\/j.ctro.2024.100848","DOI":"10.1016\/j.ctro.2024.100848"},{"issue":"9","key":"7264_CR35","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415\u201322.","journal-title":"J Nucl Med"},{"issue":"5","key":"7264_CR36","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","volume":"48","author":"W Guo","year":"2021","unstructured":"Guo W, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48(5):1604\u201317.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7264_CR37","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423\u20139.","journal-title":"J Nucl Med"},{"issue":"12","key":"7264_CR38","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/biology13120967","volume":"13","author":"J Fouillet","year":"2024","unstructured":"Fouillet J, et al. Unveiling the tumor microenvironment through fibroblast activation protein targeting in diagnostic nuclear medicine: a didactic review on biological rationales and key imaging agents. Biology. 2024;13(12):967.","journal-title":"Biology"},{"key":"7264_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/ITT.S291767","volume":"10","author":"R Bughda","year":"2021","unstructured":"Bughda R, et al. Fibroblast Activation Protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma. Immunotargets Ther. 2021;10:313\u201323.","journal-title":"Immunotargets Ther"},{"issue":"9","key":"7264_CR40","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/RLI.0000000000000666","volume":"55","author":"A Hagiwara","year":"2020","unstructured":"Hagiwara A, et al. Variability and standardization of quantitative imaging: monoparametric to multiparametric quantification, radiomics, and artificial intelligence. Invest Radiol. 2020;55(9):601\u201316.","journal-title":"Invest Radiol"},{"issue":"2","key":"7264_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1102\/1470-7330.2004.0018","volume":"4","author":"KA Vanderveen","year":"2004","unstructured":"Vanderveen KA, Hussain HK. Magnetic resonance imaging of cholangiocarcinoma. Cancer Imaging. 2004;4(2):104\u201315.","journal-title":"Cancer Imaging"},{"issue":"6","key":"7264_CR42","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1148\/rg.2021210035","volume":"41","author":"SJ Galgano","year":"2021","unstructured":"Galgano SJ, et al. Applications of PET\/MRI in abdominopelvic oncology. Radiographics. 2021;41(6):1750\u201365.","journal-title":"Radiographics"},{"issue":"7","key":"7264_CR43","doi-asserted-by":"publisher","first-page":"12913","DOI":"10.3390\/molecules200712913","volume":"20","author":"I Velikyan","year":"2015","unstructured":"Velikyan I. 68Ga-Based radiopharmaceuticals: production and application relationship. Molecules. 2015;20(7):12913\u201343.","journal-title":"Molecules"},{"issue":"11","key":"7264_CR44","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1016\/j.apradiso.2012.07.015","volume":"70","author":"J Han","year":"2012","unstructured":"Han J, et al. 18F half-life measurement using a high-purity germanium detector. Appl Radiat Isot. 2012;70(11):2581\u20135.","journal-title":"Appl Radiat Isot"},{"key":"7264_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","volume":"76","author":"A Sanchez-Crespo","year":"2013","unstructured":"Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55\u201362.","journal-title":"Appl Radiat Isot"},{"issue":"8","key":"7264_CR46","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00259-021-05646-z","volume":"49","author":"K Hu","year":"2022","unstructured":"Hu K, et al. [(18)F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [(68)Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2022;49(8):2833\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7264_CR47","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00259-022-06022-1","volume":"50","author":"J Zhang","year":"2023","unstructured":"Zhang J, et al. [18F]FAPI PET\/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity. Eur J Nucl Med Mol Imaging. 2023;50(3):937\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07264-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07264-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07264-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:05:17Z","timestamp":1756897517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07264-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7264"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07264-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review and meta-analysis and did not involve direct research on human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. This study did not involve the direct participation of individuals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. The manuscript does not include individual data requiring consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest relevant to this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"During the preparation of this work, the authors used ChatGPT- 4 solely for grammar and language improvement purposes. No assistance from this tool was employed in methodology or analysis. After using this tool, the authors reviewed and edited the content as needed and took full responsibility for the content of the published article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI in scientific writing"}}]}}